Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka AkcyjnafiledCriticalRead-Gene Spółka Akcyjna
Priority to PL433150ApriorityCriticalpatent/PL433150A1/en
Publication of PL433150A1publicationCriticalpatent/PL433150A1/en
Investigating Or Analysing Biological Materials
(AREA)
Abstract
Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia ołowiu we krwi pełnej osoby badanej, przy czym stężenie wskazuje na dwukrotnie obniżone ryzyko rozwoju raka w przypadku występowania wartości stężenia ołowiu we krwi poniżej 9,13 µg/l.The subject of the application is a method of determining cancer risk, characterized in that it includes a quantitative assessment of the whole blood lead concentration of a test subject, the concentration showing a doubled risk of developing cancer when blood lead values are below 9.13 µg / L.
PL433150A2020-03-052020-03-05Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
PL433150A1
(en)
A reappraisal of the comparative effectiveness of lumpectomy versus mastectomy on breast cancer survival: a propensity score–matched update from the National Cancer Data Base (NCDB)
Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review: M. Castelo et al.
Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations